We are live on ! Find out more
ILMN icon

Illumina

245.18 USD
+16.25
7.1%
At close Updated Sep 17, 4:00 PM EDT
Pre-market
After hours
243.40
-1.78
0.73%
1 day
7.1%
5 days
21.49%
1 month
26.94%
3 months
54.11%
6 months
102.9%
Year to date
82.49%
1 year
143.07%
5 years
-43.61%
10 years
45.57%
 

About: Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Employees: 8,650

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 59.1%
Neutral 38.6%
Negative 2.3%
Positive
Zacks Investment Research
6 days ago
Illumina (ILMN) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Illumina (ILMN) is a Top-Ranked Momentum Stock: Should You Buy?
Positive
Benzinga
8 days ago
This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Neutral
Zacks Investment Research
9 days ago
3 Stocks Soon Joining the S&P 500
The S&P 500 is set for another shakeup, with Bloom Energy (BE), Everpure (P), and Illumina (ILMN) all joining in the next quarterly rebalancing near the end of September.
3 Stocks Soon Joining the S&P 500
Positive
Zacks Investment Research
9 days ago
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
3 Promising Genomics Stocks in the Spotlight in 2026
Positive
Zacks Investment Research
10 days ago
Illumina (ILMN) Upgraded to Buy: What Does It Mean for the Stock?
Illumina (ILMN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Illumina (ILMN) Upgraded to Buy: What Does It Mean for the Stock?
Neutral
PRNewsWire
13 days ago
Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 21, 2026, to coincide with the quarterly rebalance.
Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
Neutral
Investors Business Daily
13 days ago
Bloom Energy, Illumina, Everpure Rise On S&P 500 Inclusion
AI energy play Bloom Energy will be added to the S&P 500 index on Sept. 21. Illumina and Everpure also will join.
Bloom Energy, Illumina, Everpure Rise On S&P 500 Inclusion
Neutral
Barrons
13 days ago
Bloom Energy and These 2 Stocks Are Joining the S&P 500
The S&P 500 is getting three new members this month, with Bloom Energy, Everpure, and Illumina joining the benchmark as part of its latest quarterly reshuffle.
Bloom Energy and These 2 Stocks Are Joining the S&P 500
Positive
Zacks Investment Research
13 days ago
Are Robots the New Normal? Bet on these ETFs to Invest in the Future
Robotics is entering a new era as AI fuels humanoid adoption, with four ETFs offering diversified exposure to the sector's growth.
Are Robots the New Normal? Bet on these ETFs to Invest in the Future
Positive
ETF Trends
15 days ago
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.
Why Moderna's Cancer Vaccine Matters to Investors
Price charts implemented using Lightweight Charts™